Evidence map›Paper›PMID 40959072›Full record

ArticleFrontiers in immunology2025

Safety and clinical outcomes of orelabrutinib, lenalidomide plus sintilimab for relapsed/refractory diffuse large B-cell lymphoma.

Lingling Wang, Yongfen Huang, Dan Xu, Xiaoyong Wang, Hailiang Chu, Chunling Wang, Hao Xu, Wei Sang, Yuexin Cheng, Yuqing Miao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lingling WangDepartment of Hematology, The First People's Hospital of Yancheng, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, China.
Yongfen HuangDepartment of Hematology, The First People's Hospital of Yancheng, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, China.
Dan XuDepartment of Hematology, Funing People's Hospital, Yancheng, China.
Xiaoyong WangDepartment of Hematology, Dongtai People's Hospital, Yancheng, China.
Hailiang ChuDepartment of Hematology, Bozhou Hospital Affiliated to Anhui Medical University, Bozhou, China.
Chunling WangDepartment of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China.
Hao XuDepartment of Hematology, The First People's Hospital of Yancheng, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, China.
Wei SangDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yuexin ChengDepartment of Hematology, The First People's Hospital of Yancheng, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, China.
Yuqing MiaoDepartment of Hematology, The First People's Hospital of Yancheng, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study evaluated the safety and clinical outcomes of orelabrutinib, lenalidomide plus sintilimab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Methods: Thirty-four patients were given orelabrutinib 150 mg once daily, lenalidomide 25 mg once daily on days 1-10, and sintilimab 200 mg intravenously on day 1 of each 21-day cycle. Results: With a median follow-up of 9 months (95% CI, 8.3-9.6), 7 patients died. The 1-year progression-free survival (PFS) and overall survival (OS) were 41.9% and 77.8%, respectively. The median PFS was 6 months (95% CI, 3.4-8.6), and median OS was not reached. The median exposure time was 4 months, while the median time to first response was 2 months. The best objective response rate (ORR) was 58.8%, with a complete remission (CR) rate of 38.2%. Twenty-eight (82%) patients presented with treatment-related adverse events (TRAEs), and 7 (20.6%) patients developed grade 3 or higher TRAEs. The most common grade 1 TRAEs were neutropenia (64.7%), thrombopenia (44.1%), skin rash (32.4%), and fatigue (29.4%). Patients who responded to treatment had a higher proportion of PD1 Discussion: Orelabrutinib, lenalidomide plus sintilimab demonstrated promising efficacy and a manageable safety profile in Chinese patients with R/R DLBCL.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsLenalidomideLymphoma, Large B-Cell, DiffusePyrazinesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPiperidinesPyridinesTreatment OutcomeAntibodies, Monoclonal, HumanizedLenalidomideorelabrutinibPiperidinesPyrazinesPyridinessintilimabanti-programmed cell death-1 monoclonal antibodyBruton tyrosine kinase inhibitorsdiffuse large B-cell lymphomaimmunotherapyrelapsed/refractory

Identifiers

PMID40959072
PMCPMC12434019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.